ANTITHROMBOTIC TISSUE SOLDER FOR MICROVASCULAR REPAIRS

用于微血管修复的抗血栓组织焊料

• 批准号: 2030170
• 负责人: ROBERT B STEWART
• 金额: $ 9.81万
• 依托单位: ABIOMED, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-01 至 1998-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2030170
• 关键词: albumins; anticoagulants; antithrombogenic surface; bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; fibrinolysis; heat; heparin; laboratory rat; lasers; microsurgery; surgery material /equipment

Several techniques have been explored to simplify microvascular repairs. One of these techniques, laser assisted microvascular anastomoses (LAMA) has been studied extensively, with limited clinical use. Major impediments to the acceptance of LAMA by microsurgeons were concerns with low acute tensile strength, and the subjective visual endpoint for tissue fusion. These problems have been addressed recently via the use of biological solders to increase tensile strengths, and the use of real time temperature control systems for reproducible LAMA. Whereas these improvements have increased the overall safely of the LAMA procedure, failures second-ary to the thromboses of small microvessels ( less than 0.5 mm), which are also a major problem in sutured repairs, will remain pervasive. The objective of this proposal is to integrate temperature controlled laser welding techniques with novel types of tissue solders to provide in situ delivery of antithrombotic agents at the microvascular repair site. By adding anti-coagulants or thrombolytic drugs to the tissue solders, and then thermally denaturing the bulk solders during LAMA, non-immunogenic, bioactive structure results. As the solders are denatured by the healing process, the drug should be delivered to the repair site, providing therapeutic in situ dosages. In the Phase I studies, this novel tissue repair technology will be used in a microvascular thrombosis model to measure the patency rate, as compared to sutured repairs. This new repair technology should ultimately result in significantly increased postoperative success rates for microvascular repairs. PROPOSED COMMERCIAL APPLICATION This research involves several novel technologies, whose combination may lead to a significant improvement in the clinical outcome of microvascular repairs. The use of the resulting methodology for in situ drug delivery may also be applicable to increase the postoperative success rate for the repair of larger vessels, which accounts for over 500,000 procedures per year in the U.S.

已经探索了几种简化微血管的技术 维修。 这些技术之一，激光辅助微血管 对吻合（喇嘛）进行了广泛的研究，有限 临床用途。 对接受喇嘛接受的主要障碍 微分类物是低急性拉伸强度的关注点，并且 组织融合的主观视觉终点。 这些问题 最近通过使用生物焊料来解决 增加拉伸强度和实时温度的使用 可再现喇嘛的控制系统。 而这些 改进提高了喇嘛的整体安全 步骤，失败的小小的血栓 微血管（小于0.5毫米），这也是一个主要问题 在缝合维修中，将保持无处不在。 该提议的目的是整合温度 具有新型组织类型的受控激光焊接技术 焊料可在现场提供抗血栓形剂 微血管修复部位。 通过添加抗凝剂或 将溶栓药物焊接到组织焊料，然后热 在喇嘛，非免疫原性期间贬低散装焊料， 生物活性结构结果。 当焊料被焊接变性 康复过程，该药物应递送到维修部位， 提供原位剂量。 在第一阶段的研究中， 新型组织修复技术将用于微血管 与测量通畅率的血栓形成模型相比 缝合维修。 这种新的维修技术最终应该 导致术后成功率显着提高 微血管维修。 拟议的商业应用 这项研究涉及几种新型技术，它们的技术 组合可能会导致临床的显着改善 微血管维修的结果。 产生的使用 原位药物输送的方法论也可能适用于 提高修复较大的术后成功率 船只，每年占500,000多个程序 我们。